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Summary
The GM2-gangliosidosis B1 variant occurs at an exceptionally high frequency in the northern part of Portugal.
In most patients, the disease manifests itself as a juvenile form, as opposed to the late-infantile form described
for many patients from other parts of the world. We have analyzed the 13-hexosaminidase a gene in 11 patients,
as well as in some relatives, in order to characterize the underlying abnormalities. They were screened for
the two previously identified mutations responsible for the B1 variant phenotype (G533--A, also designated
as the "DN allele," and C532-->T) by PCR amplification of an 800-bp DNA fragment and subsequent dot-blot
hybridization with allele-specific oligonucleotides. The fragment amplified from one patient was also sub-
cloned and sequenced. Ten patients, constituting a clinically and biochemically homogeneous group, were
found to be homozygous for the DN allele. The other, whose clinical profile more resembled the late-infantile
phenotype often described in the literature, was a compound heterozygote carrying the DN allele and
another, as yet unidentified, abnormal allele. Our results, corroborated by previously published data, suggest
that homozygotes and compound heterozygotes for the DN allele may be distinguishable at the phenotypic
level, depending on the nature of the abnormality in the other allele. A common ancestral origin for the DN
allele can also be postulated.
Introduction
GM2-gangliosidosis comprises a group of neurodegen-
erative disorders resulting from the genetically defec-
tive catabolism- and subsequent accumulation- of
GM2-ganglioside (Sandhoff et al. 1989). Three major
types are distinguished on the basis of the defective
genes involved: the N-acetyl-pi-hexosaminidase a-sub-
unit, or 1-subunit, and the natural activator protein,
lead respectively, to the B variant (Tay-Sachs disease),
the 0 variant (Sandhoff disease), and the AB variant.
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The B1 phenotype is among the variant forms of
the genetic 1-hexosaminidase a defects. It is enzymo-
logically unique in that 13-hexosaminidase A is catalyt-
ically normal if tested with conventional artificial
substrates but is inactive to hydrolyze natural GM2-
ganglioside and sulfated artificial substrates (e.g.,
4-MU-GlcNAc-6-sulfate) (Kytzia et al. 1983). Ohno
and Suzuki (1988) described the first causal mutation
in the a-subunit gene associated with the B1 pheno-
type in a Puerto Rican patient (DM). This point muta-
tion, designated as the "DN allele," was a G-to-A
transition at nucleotide 533 (counted from A of the
initiation codon, ATG), translating into an arginine-
to-histidine substitution at residue 178. Computerized
molecular modeling of this region revealed drastic al-
terations in the three-dimensional structure of the mu-
tant protein (Suzuki and Vanier, in press), consistent
with the hypothesis that this region defines a function-
ally important domain of the a-subunit (Ohno and
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Suzuki 1988). In subsequent studies, the same DN
allele was found in six B1 variant patients of diverse
ethnic and geographical origins (Tanaka et al. 1988),
and a different point mutation (C532 to T) affecting
the same codon (Argt78 to Cys) was identified in a
Czechoslovakian patient (Tanaka et al. 1990). Except
for a Spanish patient who was a DN-allele homozy-
gote, all others were compound heterozygotes (Ta-
naka et al. 1990).
The finding of the wide distribution of the DN allele
was somewhat surprising and was difficult to attribute
to a coincidence in independent sporadic mutational
events, even though it involves a CpG mutation hot
spot. On the other hand, although three of these seven
patients could be considered to be of "Hispanic" back-
ground (Puerto Rican, Spanish, and English/French/
Azorean), it seemed unlikely that the allele had derived
from a single ancestor. The present report describes a
further study of 11 additional B1 variant patients from
eight apparently unrelated families originating from a
defined region in the north of Portugal. We hypothe-
size a common origin for this mutation, in view of
both the unusually large number of homozygotes in
this area and the migratory routes which link the Por-
tuguese to some ethnicities of the previously described
cases. This work was presented in part at a meeting
and was published in an abstract form (Dos Santos et
al. 1990).
Patients, Material, and Methods
Patients
Altogether, 11 patients from eight different families
were studied, including the seven patients described
both above and elsewhere (Maia et al. 1990). The
clinical and enzymological data on these patients are
summarized in table 1. Patient 11 presented a clinical
and biochemical profile of the late-infantile form of
the disease, while all other patients were of the juvenile
phenotype. The molecular studies also included par-
ents and unaffected siblings in some families. Enzy-
matic assays were done as described elsewhere (Maia
et al. 1990).
Lymphoblast Cultures
Epstein-Barr Virus (EBV)-transformed lympho-
blast cell cultures were used as source material for
DNA from all individuals. The cell lines were estab-
lished starting from 5 ml of whole blood, according to
Table I




PRESENT AGE OR 4-MU-GIcNAc Sulfated
CASEa (sex) INITIAL SYMPTOM AGE AT ONSET AGE AT DEATH Total % A (Hex A)
1 (F)............. Gait disturbance 3 years 11 years (deceased) 987 69.6 .99
2 (F)............. Gait disturbance 3-4 years 12 years 1,340 76.3 .80
3 (F)............. None (presymptomatic) ... 4 1/2 years 1,220 70.1 2.90
4 (F)............. Language delay 4-5 years 13 years (deceased) 914 60.6 .62
5 (M) ........ Gait disturbance 6 years 12 years 967 66.0 1.90
6 (M) ........ Speech loss 7 years 16 years 1,030 60.3 .59
7 (F)............. Speech loss 4 years 9 years 1,010 66.0 .75
8 (M) ........ ?? ?? 8 years 1,050 59.0 1.50
9 (F)............. Gait disturbance 5 ½/2 years 763 67.6 2.70
10 (M)........ Gait disturbance 3 years 10 years 785 54.0 1.96
11 (F)........... Gait disturbance 14 mo 4 years 1,300 24.4 4.00
a Three pairs of patients-2 and 3, 6 and 7, and 9 and 10-are siblings. The parents of patients 9 and 10 are consanguineous. All families
were from the following towns and villages, either in the district of Braga (cases 1-7) or in the district of Porto (cases 8-11), all of which
are within 100 km from the city of Porto: Amarante (case 1), Braga (cases 2, 3, and 5), Vila Nova Famalicao (case 4), Celorico de Bastos
(cases 6 and 7). Gondomar (case 8), Villa Nova Gaia (cases 9-11).
b Determined in leukocytes. The ranges of the control activities (n = 54) were 967-2,294 (total), 80.8-91.4 (% A), and 128-319 (sulfated
substrate).
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an modification of the method described by Neitzel
(1986). EBV was harvested from the culture medium
of cell line B95-8. Transformed lymphocytes were
grown in RPMI-1640 (Roswell Park Memorial Insti-
tute series) medium + antibiotics + 10% inactivated
FCS, which was supplemented with 2 Rg cyclosporin
A/ml during the first week following infection.
Screening with Allele-specific Oligonucleotides (ASO)
Genomic DNA was isolated from approximately
40 ml of saturated lymphoblast suspension cultures,
according to the standard procedure (Maniatis et al.
1982). An approximately 800-bp fragment, including
exon 5 of the 13-hexosaminidase a gene, was ampli-
fied by the PCR with appropriate primers and was
screened for both the DN allele and the Czechoslova-
kian allele by dot-blot analysis (Tanaka et al. 1990).
Sequencing
The amplified 800-bp fragment was digested with
BamHI to generate two fragments, one of about 200
bp and one of about 600 bp. The mutation site is
located on the larger fragment, approximately 100 bp
downstream of the cleavage site. This fragment was
subcloned into pUC19 and sequenced directly in the
plasmid DNA by means of the dideoxy chain-
termination method (Sanger et al. 1977), with 35S-
labeled dATP (Biggin et al. 1983), by using the 17-mer
universal primer and T7 DNA polymerase.
Results
PCR amplification and dot-blot analysis with the
three ASOs indicated that, in all patients except for
patient 11, positive signals were obtained for the DN
allele only (fig. 1). The phenotypically different patient
11 was clearly a compound heterozygote in that posi-
tive signals were present for both the normal allele and
the DN allele (fig. 1). All other patients either were
homozygous for the DN allele or were compound het-
erozygotes, possessing one DN allele and another ab-
normal allele with a mutation within the 21-bp region
spanned by the ASOs, which was neither the DN nor
the "Czechoslovakian" mutation. This ambiguity was
resolved for most patients by examining both parents,
who were found to be carriers of theDN allele, thereby
allowing the confirmation of homozygosity in their
offspring (fig. 1). In one patient (patient 5), whose
parents could not be studied, sequencing was carried
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Figure I Dot-blot analysis using allele-specific probes for
DN mutation and for normal sequence. Samples are blotted in dupli-
cate. Technical details are described in the text. Case numbers are
as in table 1. The positive control is the Spanish patient who is
homozygous for theDN allele (Tanaka et al. 1990), and the negative
control is a normal individual. GM2-gangliosidosis * = patient with
atypical but non-B1 variant GM2-gangliosidosis. Although not
shown, the parents of patient 4 and those of patients 6 and 7 were
also all carriers of the DN mutation. The parents of patient 5 were
not tested, but four independent subclones of this patient all showed
the DN mutation. Thus, patients 2-10 were all homozygous for the
DN allele. In contrast, patient 11 is clearly a compound heterozy-
gote with only one allele carrying the DN mutation. No individuals
gave a positive signal for the Czechoslovakian mutation.
tive subclones all exhibited the DN mutation (results
not shown). Although no biological material was
available for one of the patients (patient 1), DNA sam-
ples were obtained from both of her parents and from
her three sibs. Figure 2 shows that both parents carry
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Figure 2 Dot-blot analysis of family members of patient 1
by using allele-specific probes for DN mutation and for normal
sequence. Specimens were not available from patient 1. Thus, sam-
ples from the parents and from three unaffected siblings were
screened according to the methods described in the text. The posi-
tive and negative controls are as in fig. 1. Both parents are carriers
of the DN allele. Sister 1 is normal, while both sister 2 and sister
3 are carriers.
the DN mutation, and it was thus concluded that the
deceased patient was also a DN-allele homozygote.
These analyses also established the carrier status in
two siblings, where previous biochemical studies had
been inconclusive, because of overlapping of the value
ranges obtained in control and carrier individuals
fig. 2).
Discussion
Two causal mutations had previously been identi-
fied in patients presenting the B1 variant phenotype of
GM2-gangliosidosis (Tanaka et al. 1988, 1990). Both
were single-base substitutions at the codon for Arg'78.
The DN allele, a G533-to-A mutation which was first
identified in a Puerto Rican patient, was reported to
be present in six of the seven patients studied. All were
compound heterozygotes, except for a Spanish patient
who was homozygous for the DN allele. Among the
compound heterozygotes, the nature of the second
mutant allele was identified only in the original Puerto
Rican patient, who had the exon 11 four-base inser-
tion commonly associated with the infantile Jewish
Tay-Sachs disease (Tanaka et al. 1990). In contrast,
10 of 11 patients in the present study were DN-allele
homozygotes.
All 11 DN-allele homozygous patients (10 in the
present study and the Spanish patient in Tanaka et al.
1990) were of the juvenile clinical phenotype with a
late onset and slow progression. The original Puerto
Rican patient, who had theDN mutation and an infan-
tile mutation in the respective alleles, had a late-
infantile form of the disease in that onset was at 11
mo, and death occurred at 4 years 8 mo. In the present
study, the compound heterozygous patient (patient
11) showed a similar clinical profile, with onset at 14
mo and a rapidly progressive deterioration. Clinical
phenotypes of the remaining compound heterozygous
patients were variable. These observations suggest a
genotype-phenotype correlation. In the homozygotes,
the total residual activity ofthe mutant enzyme protein
generated by the double dose of the DN allele presum-
ably is sufficient for the juvenile phenotype. On the
other hand, the clinical phenotype of DN-allele com-
pound heterozygotes should depend on the nature of
the second abnormal allele. When the second allele
contributes no residual activity at all, such as in the
original Puerto Rican patient, the disease will be of an
earlier onset and more rapid progression but will not
be as severe as in patients in whom neither allele gener-
ates residual activity, such as in classical infantile
Tay-Sachs disease. If the second allele carries any mu-
tation that can also contribute residual catalytic activ-
ity, the clinical phenotype can be expected to be corre-
spondingly milder.
The exceptionally large number of Bi-variant pa-
tients in a defined region of Portugal was unexpected
for this presumably very rare disease. Consanguinity
was found in only one of the eight families, which is
indicative of an unusually high gene frequency in this
area. A project is currently being undertaken to screen
the local population by biochemical assays in urine
samples (Ribeiro et al., submitted). Carriers detected
in this way will subsequently be tested for presence of
the DN allele by the oligonucleotide probes.
Considering that there is no positive record of relat-
edness among the families and that 10 patients are
DN-allele homozygotes and that one is a DN-allele
compound heterozygote, it appears that the mutation
has been present in this population for some time. In
keeping with the hypothesis of a common ancestral
origin, the diverse migratory routes of the Portuguese
could perhaps account for the mutation's wide geo-
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graphic and ethnic distribution. The presence of the
DN allele in at least some of the previously described
cases- i.e., the Spanish patient (both parents originat-
ing from a Spanish village 15 km from the Portuguese
border), the Puerto Rican patient (a large number of
Portuguese emigrated to Puerto Rico around 1700),
and the English/French/Azorean patient (whose ma-
ternal and paternal grandparents are from the Portu-
guese archipelago of Azores) -could be explained on
this basis. Analysis of conserved sequences around the
gene locus could contribute toward testing this hy-
pothesis. Until such studies are undertaken, it is
difficult to prove that in all instances the allele might
have been inherited from a single ancestor. Mean-
while, this is considered a more plausible explanation
for its wide distribution than ascribing the finding to
numerous independent G533-to-A mutations.
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